SUNNYVALE, California - Data show superiority of endoscopic ablation therapy using the HALO System for eradicating Barrett’s esophagus in randomized, multicenter, sham controlled trial
Results from a clinical study published today in the New England Journal of Medicine reveal that ablative therapy using the HALO system (BARRX Medical, Inc.) is highly effective for complete eradication of a pre-cancerous condition of the esophagus called Barrett’s esophagus afflicting more than 3.3 million Americans. Additionally, ablative therapy using the HALO system reduced the risk of progression to cancer in the highest risk cohort studied (compared to control) from 19.0% to 2.4%.
The study entitled “Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia” is authored by lead investigator Nicholas J. Shaheen, M.D., Associate Professor of Medicine and Epidemiology, The University of North Carolina in Chapel Hill.
“This is a well-designed trial conducted in a rigorous manner at 19 expert U.S. centers, each having experience in the management of Barrett’s esophagus, dysplasia, and cancer,” said Dr. Shaheen. “Our results reported in the Journal are very promising, demonstrating superiority of ablation therapy for eliminating Barrett’s and dysplasia, as well as reducing the rate of disease progression to more severe forms of dysplasia and esophageal cancer. This and data from other recent trials may ultimately change the paradigm for how gastroenterologists manage their patients with this disease.”
As a result of chronic injury from gastroesophageal reflux disease (GERD), the normal esophageal lining is replaced with abnormal cells (Barrett’s tissue), predisposing the patient to a higher risk for developing cancer of the esophagus. Patients with Barrett’s who develop cancer, typically do so through a series of steps, starting with early Barrett’s, then low-grade dysplasia or high-grade dysplasia, and then finally cancer. The present study included patients with the later stages of low- and high-grade dysplasia.
Beginning in 2006, the AIM Dysplasia Trial enrolled 127 patients having a diagnosis of Barrett’s esophagus with dysplasia, the most advanced stage of this condition. Patients were randomly assigned to receive either endoscopic ablation with the HALO system or a sham intervention (control, no treatment). Tissue samples (biopsies) were obtained from the esophagus at regular intervals for one year after enrollment to assess for the presence of early Barrett’s, dysplasia, and esophageal cancer. Comparison of the biopsy results at one year served as the primary outcome for the trial. The study endpoints were the eradication of all early Barrett’s and, separately, all dysplasia in each group, as well as occurrence of new esophageal cancers.
At one-year follow-up, patients treated with ablation had a significantly higher complete eradication rate for both early Barrett’s and dysplasia as compared to the control group. More than three quarters of treated patients had no detectable Barrett’s at the end of the treatment period, compared to sham patients where 98% had persistent disease. The overall rate of disease progression to more severe forms of dysplasia and cancer was significantly lower in the ablation treatment group (3.6%) as compared to the control group (16.3%). In the highest risk cohort (high-grade dysplasia), ablative therapy significantly reduced the risk of progression to cancer by nearly 90% compared to control (2.4% in treated patients versus 19.0% in untreated controls).
About BARRX Medical, Inc.
BARRX Medical, Inc. develops treatment solutions for Barrett’s esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO360 System, provides a uniform and controlled ablation effect, which removes the diseased tissue and allows regrowth of normal cells. In the largest clinical trial conducted and published to date (the AIM-II Trial), 98.4 percent of patients were Barrett’s-free after two and a half years of follow-up. The HALO90 System is the company’s second ablation product, which is mounted on the end of an endoscope and used to treat smaller, non-circumferential areas of disease.
Both HALO systems are cleared by the FDA for use in the U.S. and both have CE Mark for use in Europe. More than 30,000 procedures have been performed in over 280 hospitals around the world. Based in Sunnyvale, Calif., BARRX Medical, Inc. was founded in 2000 and is privately-held. Additional information is available at www.barrx.com.
About the New England Journal of Medicine
The New England Journal of Medicine (N Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely read peer-reviewed general medical journals in the world. It is also the oldest continuously published medical journal in the world. The journal usually has the highest impact factor of all journals of clinical medicine; in 2006, the impact factor was 51, according to Journal Citation Reports, the first research journal to break 50.
Source: BARRX Medical, Inc.
media, Kevin Knight, +1-972-385-9384, mobile, +1-214-732-9392, kmcinc at aol.com, for BARRX Medical, Inc.; or Gregory A. Barrett of BARRX Medical, Inc., +1-408-328-7308, gbarrett at barrx.com
Related Press Releases
Cancer Protection Supported by UV ExposureSeptember 22nd, 2009 VELDHOVEN, The Netherlands - Regular, moderate UV exposure contributes to protection against breast, prostrate and colorectal cancer (colon and rectal cancer) as well as non Hodgkin's lymphoma (one of two forms of lymph node cancers). A team of Dutch scientists led by Han von der Rhee from the Haager clinic group "Hagaziekenhuis" and the University of Rotterdam came to this conclusion in a study that has now been published in the specialist magazine "European Journal of Cancer Prevention".
Clinical Study Proves Pollogen's TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch MarksAugust 17th, 2009 TEL AVIV, Israel -
- Results Published in the Online Edition of the Journal of Dermatological Treatment
Pollogen's TriPollar(TM) technology, the most advanced 3rd generation radio frequency solution for facial and body contouring, has been clinically proven to be effective in treating stretch marks or striae distensae. The peer reviewed paper entitled "Treatment of striae distensae with a TriPollar radiofrequency device: a pilot study" authored by Dr Manuskiatti et al, has been published in the Journal of Dermatological Treatment.
James Corden Says "Let's Eat Cake!" Local Supporters Bake a Cake for CharityJune 18th, 2009 LONDON - Local charity supporters are baking cakes to raise vital funds for bone cancer research which most commonly affects teenagers and young people aged between 10 and 25. Tea parties, cake sales, auctions, and picnics are just a few of the events organised by supporters of the Bone Cancer Research Trust as part of its Awareness Week 20th - 27th June.
Bone Cancer Research Trust Calls for New Treatments for Bone CancerJune 17th, 2009 LONDON - The Bone Cancer Research Trust is calling for new treatments for bone cancers affecting children and young people. This includes osteosarcoma and Ewing's sarcoma, the two most common forms of primary bone cancer.
Advance in Bowel Cancer Test ResearchJune 4th, 2009 SYDNEY - Australian researchers have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous controls. Being presented today at the Digestive Disease Week conference in Chicago, the preliminary findings are the result of a collaborative study - involving CSIRO, Flinders University and Australian healthcare company, Clinical Genomics Pty Ltd - designed to develop an improved screening/diagnostic test for detecting bowel cancer and significant pre-cancer lesions.
Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal SurgeonsJune 2nd, 2009 SUNNYVALE, California - Radiofrequency ablation is durable after 2 years, compares favorably with endoscopic resection for advanced disease, and reduces the risk for cancer progression
Results from a number of clinical trials were presented during the Digestive Disease Week (DDW) in Chicago this week, revealing new outcomes data related to endoscopic radiofrequency ablation using the HALO ablation system for eradicating a pre-cancerous esophageal condition known as Barrett's esophagus. Among them, reports included durability outcomes from a randomized sham-controlled trial, safety and efficacy outcomes from a large U.S.
Randomized Controlled Trial of Radioactive Resin Microspheres Demonstrates Significant Delay in Progression of Disease in Patients With Colorectal Cancer Liver Metastases who Have Exhausted ChemotherapyMay 31st, 2009 ORLANDO, Florida - The time to progression of disease in patients with colorectal cancer liver metastases who have exhausted all chemotherapy options can be more than doubled through the use of radioactive resin microspheres, according to the results of a prospective randomized controlled trial presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).[1] The multicenter phase III study compared the use of 5-fluorouracil (5FU) alone to 5FU plus 90Y resin microspheres (SIR-Spheres; Sirtex Medical, Sydney) and was conducted by a collaboration of university hospitals in Belgium. "Patients with colorectal cancer liver metastases who are resistant or intolerant of chemotherapy should be considered for salvage therapy using 90Y resin microspheres combined with 5FU-based chemotherapy," said Dr Alain Hendlisz, Head of Digestive Oncology and Gastroenterology at Institut Jules Bordet Université Libre de Bruxelles, Brussels, Belgium, and principal investigator of the study.
Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barrett's EsophagusMay 31st, 2009 SUNNYVALE, California - Large multi-center trial conducted in a community practice setting demonstrates comparable outcomes as trials conducted in predominantly tertiary academic centers
Clinical trial results presented at the Digestive Disease Week in Chicago today reveal that endoscopic radiofrequency ablation performed in a community practice setting is safe and effective for eradicating a pre-cancerous esophageal condition known as Barrett's esophagus. The study is entitled, "Radiofrequency Ablation of Barrett Esophagus: Outcomes of 429 Patients from a Multi-center Community Practice Registry" and was presented today by Ronald E.
Bariatric Surgery as a Cure for Diabetes: Can we Stomach it?March 23rd, 2009 LONDON - For the first time ever, experts in bariatric surgery gave a lecture on
how weight loss surgery for morbidly obese patients can cure type 2 diabetes,
at the Diabetes UK Annual Professional Conference in Glasgow. 'The changing face of diabetes', was the theme for the 2009 conference,
introducing the new developments in bariatric research and clinical practice
for the future.
PSA Screening Cuts Deaths by 20%, Says World's Largest Prostate Cancer StudyMarch 17th, 2009 STOCKHOLM, Sweden - Attn: Healthcare Editors
Screening for prostate cancer can reduce deaths by 20%, according to the
results of the European Randomized Study of Screening for Prostate Cancer
(ERSPC) published online 1700 hours CET 18 March (NEJM, Online First*). ERSPC
is the world's largest prostate cancer screening study and provides robust,
independently- audited evidence, for the first time, of the effect of
screening on prostate cancer mortality.
Related News
New drug shows promise to reduce stroke riskAugust 31st, 2009 LONDON - A new drug developed as an alternative to popular drug warfarin, also used as rat poison, has been found to significantly reduce stroke risk. Generally, patients at risk of stroke are given warfarin to prevent blood clotting, but the treatment is risky and requires regular monitoring.
Experimental drug found effective against anthrax poisoningJuly 10th, 2009 LONDON - An experimental drug called raxibacumab has been found to be effective in treating anthrax poisoning, say researchers. "The results published today showed that a single dose of raxibacumab was highly effective as a treatment for inhalation anthrax in both rabbits and monkeys," said Dr Sally D.
Face protection effective in influenza preventionMay 21st, 2009 WASHINGTON - A new study has suggested that face protection is a key infection control measure for influenza. Lawrence M. Wein, Ph.D., and Michael P.
Study shows experimental drug cuts stroke risk in patients with irregular heartbeatsAugust 30th, 2009 Study shows experimental drug cuts stroke riskBARCELONA, Spain — An experimental drug reduces the stroke risk in patients with irregular heartbeats by nearly four times, compared with the popular drug warfarin — but possibly at a cost, according to new research released Sunday. Patients taking the new drug dabigatran etexilate, made by German pharmaceutical Boehringer Ingelheim, also were slightly more likely to have heart attacks or stomach pain, according to the research presented at the European Society of Cardiology meeting in Barcelona.
Experimental drug shows promise in treating head, neck cancersApril 29th, 2009 WASHINGTON - An anti-cancer compound studied for treating blood cancers may also help in treating cancers of the head and neck, say researchers at Albert Einstein College of Medicine of Yeshiva University. The study involved a new class of chemotherapy agents known as histone deacetylase (HDAC) inhibitors, which affect the availability of genes that are transcribed and translated into proteins.
Extract of Kava may help beat the bluesMay 12th, 2009 WASHINGTON - A traditional extract of Kava, a medicinal plant from the South Pacific, may be safe and effective in reducing anxiety as well as depression, a study has found. In the study, researchers at the University of Queensland in Australia found that a water-soluble extract of Kava was effective in treating anxiety and improving mood.
Indians living in UK and Wales at greater risk of drink-related deathMarch 20th, 2009 WASHINGTON - Men born in India, but living in England and Wales, are twice as likely to die alcohol-related deaths as the rest of the population, according to a new study led by an Indian-origin scientist. Conducted by the University of Edinburgh and the Office for National Statistics, the research also found that an equal number of alcohol-related deaths in England and Wales were reported among people born in Scotland or Ireland.
New RNA treatment can shrink cancersMarch 20th, 2009 WASHINGTON - A newly-identified type of microRNA could tackle aggressive cancers by helping to kill off their cells. 'MicroRNAs are very small, newly-identified RNA elements of the cell, and we've shown that one in particular - microRNA-7 or miR-7, can play a profound role in reversing cancer cell growth,' said Peter Leedman, a professor who led the research team.
60-year-old drug may help treat deadly cancersAugust 27th, 2009 WASHINGTON - A drug developed back in 1940s has a potential to treat some of the most deadly cancers, it has emerged. Scientists from Institute of Cancer Research in London have discovered that methotrexate, a chemotherapy treatment invented in the 1940s, has the potential to work against a genetic fault called HNPCC.
New anti-clotting drug reduces heart patients' chances of dyingAugust 30th, 2009 New drug reduces risks for heart patientsBARCELONA, Spain — A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared to the standard treatment, new research says. Researchers followed 18,624 patients worldwide from 2006 to 2008.
